157 related articles for article (PubMed ID: 30916605)
1. Sustained Anti-Vascular Endothelial Growth Factor Activity of Aflibercept (Eylea) After Storage in Polycarbonate Syringes Used for Intravitreal Injection: A Pathway to Safety and Efficiency.
Han DP; Skumatz C; Besharse JC; Kassem IS
J Ocul Pharmacol Ther; 2019 Jun; 35(5):278-282. PubMed ID: 30916605
[No Abstract] [Full Text] [Related]
2. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.
Lode HE; Gjølberg TT; Foss S; Sivertsen MS; Brustugun J; Andersson Y; Jørstad ØK; Moe MC; Andersen JT
Sci Rep; 2019 Dec; 9(1):18021. PubMed ID: 31792234
[TBL] [Abstract][Full Text] [Related]
3. Long-term in vitro functional stability of compounded ranibizumab and aflibercept.
Cao S; Cui J; Matsubara J; Forooghian F
Can J Ophthalmol; 2017 Jun; 52(3):273-276. PubMed ID: 28576208
[TBL] [Abstract][Full Text] [Related]
4. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
[TBL] [Abstract][Full Text] [Related]
5. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
Tschulakow A; Christner S; Julien S; Ludinsky M; van der Giet M; Schraermeyer U
PLoS One; 2014; 9(11):e113701. PubMed ID: 25415380
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of aflibercept (EYLEA
Schicht M; Hesse K; Schröder H; Naschberger E; Lamprecht W; Garreis F; Paulsen FP; Bräuer L
Ann Anat; 2017 May; 211():135-139. PubMed ID: 28279730
[TBL] [Abstract][Full Text] [Related]
7. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
8. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
[TBL] [Abstract][Full Text] [Related]
9. Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes.
Obata S; Kakinoki M; Sawada O; Kawamoto I; Murase M; Ohji M
J Ocul Pharmacol Ther; 2023 Apr; 39(3):225-228. PubMed ID: 36862540
[No Abstract] [Full Text] [Related]
10. Bevacizumab for Intravitreal Injection: Impact of Sub-Visible Particles on the Shelf-Life of Repackaged Bevacizumab.
Crul M; Zandvliet A; Moes JR; Veenbaas T; Smeets O
J Ocul Pharmacol Ther; 2019; 35(6):372-375. PubMed ID: 31259653
[No Abstract] [Full Text] [Related]
11. Aflibercept for the treatment of neovascular age-related macular degeneration.
Verner-Cole EA; Davis SJ; Lauer AK
Drugs Today (Barc); 2012 May; 48(5):317-29. PubMed ID: 22645720
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding.
de Lima Farah J; Sano R; Maugéri IML; Teixeira D; Ishimura ME; Martins G; Mimica LMJ; da Silva CB; Meyer CH; de Oliveira Dias JR; de Andrade GC; Farah ME
Int J Retina Vitreous; 2018; 4():39. PubMed ID: 30386633
[TBL] [Abstract][Full Text] [Related]
13. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties.
Sivertsen MS; Jørstad ØK; Grevys A; Foss S; Moe MC; Andersen JT
Sci Rep; 2018 Feb; 8(1):2101. PubMed ID: 29391560
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept efficacy in refractory choroidal neovascularization.
Brănişteanu DC; Bîlhă A; Moraru A
Rom J Ophthalmol; 2016; 60(2):96-102. PubMed ID: 29450330
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of aflibercept and conbercept in diabetic macular edema.
Cai S; Yang Q; Li X; Zhang Y
Drug Des Devel Ther; 2018; 12():3471-3483. PubMed ID: 30410308
[TBL] [Abstract][Full Text] [Related]
17. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
18. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
Fauser S; Muether PS
Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
20. Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.
Park SJ; Choi Y; Na YM; Hong HK; Park JY; Park KH; Chung JY; Woo SJ
Invest Ophthalmol Vis Sci; 2016 May; 57(6):2612-7. PubMed ID: 27258433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
